The maximum dosage for certain medications can reach up to 15 mg weekly, though effective weight loss is often achieved at lower doses
At six weeks, repeat the metabolic panel and lipid panel
Atypical presentation of a preexisting pancreatic pseudocyst with glucagon-like peptide-1 agonist as a possible trigger for exacerbation: a case report
7 Despite the growing evidence of the CV benefits of GLP-1 RAs and dual glucose-dependent insulinotropic polypeptide (GIP) receptor agonists/GLP-1 RAs in T2D patients and their inclusion in guidelines, lack of awareness of the CV benefits of GLP-1 RAs and dual GIP/GLP-1 RAs, clinical inertia, resistance to injectable medications and concerns about treatment costs have hindered the widespread adoption of GLP-1 RAs
Several states (e.g., North Carolina, California, Connecticut, Rhode Island, Michigan) have paused or proposed ending Medicaid coverage for GLP1 drugs for weight loss due to escalating costs, while continuing coverage for diabetes or cardiovascular risk indications
Anti-inflammatory mechanism at low doses The anti-inflammatory effects of GLP-1R agonism are not dose-dependent in the same way that weight loss is
